ABSTRACT The reabsorption of 5-methyltetrahydrofolic acid (5-CH3-H<jPteGlu) by the renal proximal tubule has an important role in the maintenance of plasma folate concentrations. However, the mechanism by which this vitamin traverses the renal epithelium re mains to be determined. Studies in cultured cells have suggested that the folate receptor in association with a probenecid-sensitive aniÃ³ncarrier may be involved in the transmembrane transport of the vitamin. Because 5-CH3-H4PteGluis reabsorbed and metabolized in the isolated perfused rat kidney (IPRK) in a similar manner to in vivo models, the IPRK was used to evaluate path ways involved in folate reabsorption. Reabsorption of 5-CH,-H.,PteGlucould not be saturated in the isolated perfused rat kidney, even at concentrations up to 2 jumol/L. Folie acid (PteGlu) was used as a competitive inhibitor of FR-dependent reabsorption of 5-CH3-H4PteGlu. When 5-CH3-H4PteGluwas maintained at 1 nmol/L (a concentration at which receptor-mediated transport should be maximal), PteGlu (up to 100 nmol/ L) had no effect on reabsorption. The addition of pro benecid (1 mmol/L) did not affect the reabsorption of 5-CH,-H,PteGlu but inhibited the fractional excretion of the aniÃ³npara-aminohippurate. Probenecid also in hibited the urinary excretion of 5-CH3-H4PteGlumetab olites, indicating that reabsorbed 5-CH3-H4PteGluwas metabolized to products that were subsequently se creted into the urine by aniÃ³nexchange pathways. The physiological importance of a folate receptor-mediated reabsorption of 5-CH3-H4PteGluappears to be minor in the isolated perfused rat kidney, whereas nonspecific pathways appear to play a major role in the renal folate reabsorption. J. Nutr. 126: 242-250, 1996. 
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â€¢probenecid â€¢renal folate reabsorption â€¢membrane folate transport â€¢rais Renal conservation of 5-methyltetrahydrof olic acid (5-CH3-H4PteGlu)5 the transportable form of folate, is an important component in maintaining plasma levels of this essential vitamin. The vitamin is effec tively conserved under normal physiologic states. However, homeostasis may be altered by a variety of stresses. Increased urinary excretion of 5-CH3-H4PteGlu, which occurs with pregnancy (Landon and Hytten 1971) and alcoholism (McMartin 1984; McMartin et al. 1986 ), has been shown to diminish plasma levels of folate in humans and animals. The increased urinary excretion of folates under these conditions has been implicated as a mechanism for the development of folate deficiency. Thus, tubular reabsorption of 5-CH3-H4PteGlu must be an efficient process to maintain proper homeostasis of the vitamin.
The precise mechanism for the cellular transport of folates and hence for the tubular reabsorption of the vitamin remains to be elucidated. Several possible pathways have been described, all of which include carrier-mediated components of transport (Antony et al. 1985 , Hjelle et al. 1991 , Kamen et al. 1988 . The folate receptor (FR),also known as folate binding pro tein, is abundant in the proximal tubule of the rat kid ney (Selhub and Franklin 1984) and other tissues in volved in the transport of the vitamin (Antony et al. 1982 , Spector 1977 tegral membrane protein anchored by a glycosyl-phosphatidylinositol linkage (Lacey et al. 1989) . Tissue culture studies have demonstrated that FR-mediated transport is responsible for the cellular accumulation of the vitamin (Antony et al. 1985 , Kamen et al. 1988 ) via a unique receptor-mediated endocytotic process. In addition, studies have suggested that a probenecidsensitive aniÃ³ncarrier may work in tandem with the FR to transfer the ionized molecule across the mem brane barrier (Kamen et al. 1991) . However, these studies have been conducted in cell lines which have the potential limitation of an unphysiologic overexpression of FR numbers on the cell surface (Antony et al. 1985 , Kamen et al. 1988 . Thus the data from cell lines are difficult to extrapolate to the in vivo set ting. The isolated perfused rat kidney (IPRK) model, which retains function similar to that seen in vivo, has been used by our laboratory to examine the renal han dling of 5-CH3-H4PteGlu (Muldoon et al. 1992) . Renal folate processing occurs primarily in the proximal tu bule, where function remains stable over periods of time in the IPRK (Maack 1980) . Previous results (Muldoon et al. 1992 ) have shown that 5-CH3-H4PteGlu is reabsorbed and metabolized in the IPRK similarly to in vivo models (Eisenga et al. 1989b , Selhub et al. 1987 . Furthermore, these studies identified a high capacity nonsaturable component at the low concentrations (Muldoon et al. 1992) . The goal of the present studies was to determine the relative impor tance of the FR and aniÃ³ncarrier in the reabsorption of 5-CH3-H4PteGlu by the IPRK under "physiologic" conditions.
MATERIALS AND METHODS
Chemicals. 5-FormyltetrahydrofoÃ-ate (5-HCOH4PteGlu), tetrahydrofolate (H4PteGlu), 5-CH3-H4-PteGlu and folie acid (PteGlu) were purchased from Sigma Chemical (St. Louis, MO). The 10-formyltetrahydrofolate (10-HCO-H4PteGlu) was synthesized in the manner of Rabinowitz (1963) . The concentration and purity of standard solutions were determined by UV spectroscopy and HPLC, respectively. Glucose oxidase, peroxidase, 2,2'-amino-bis(3-ethylbenz-thiazoline-6-sulfonic acid) Diammonium Salt, and probenecid were purchased from Sigma Chemical. The [3', 5', 7, (Muldoon et al. 1992) . In brief, the ureter was cannulated with PE-10 tubing to allow collection of urine samples. The right kidney was cannulated with a 19-gauge needle via the superior mesenteric artery to maintain constant flow. The kidney was excised and flushed with blank perfusate prior to placement in the perfusion appa ratus.
Perfusate. Kidneys were perfused with a modified Krebs-Henseleit buffer solution with the following composition (mmol/L): NaCl, 131.5; KC1,4.8; CaCl2, 2.5; MgSO4/ 1.2; KH2PO4, 1.0; NaHCO3, 13.6; and DGlucose, 5.0; plus 50 g/L Pentex bovine albumin frac tion V (Miles, Kankakee, IL). The perfusate was dialyzed overnight (Spectra/Por 1 dialysis membrane tubing, molecular weight cutoff: 6000-8000, Baxter, McGaw Park, IL) against 4 L of perfusion buffer with out albumin, filtered (Millipore, 0.2^m pore radius), oxygenated (95% O2/5% CO2) and warmed (37Â°C) by recirculation in the perfusate apparatus. Then [14C]-inulin (18.5 kBq) and [3H]-5-CH3-H4PteGlu (111 kBq, with appropriate unlabeled 5-CH3-H4PteGlu) were added to the perfusate for folate clearance studies, while [14C]-PAH(20.4 kBq with unlabeled PAH to a concentration of 20 Â¿tmol/L) and [3H]-inulin (21 kBq) were added for PAH clearance studies. PteGlu or probenecid, dissolved in 1.5 mL of dilute NaOH solution, was added depending on the experimental protocol. The radiolabeled tracers with or without PteGlu or probenecid were added 15 min prior to cannulation of the kidney and allowed to equilibrate during the perfusate recirculation.
Experimental designs. Renal folate clearance studies were performed after a stabilization period of 20 min. The 80-min experimental period was divided into 20-min urine collection intervals. Urine samples were analyzed for pH and volume, aliquots removed for scintillation counting and glucose determination, and 2-mercaptoethanol (2-ME, 50 nL/mL urine) was added to urine samples for preservation for folate analysis. Midpoint perfusate samples were collected, aliquots removed for scintillation counting and glu cose analysis, and the remainder, after addition of 50 L of 2-ME, was heat-treated (5 min, 95Â°C) to remove MULDOON ET AL. 1 Perfusions consisted of four 20-min collections after initial equilibrium period. Values represent the means Â± SEMof 15 kidneys. Kidneys from the various 5-CH3-H4PteGlu concentrations 11-2000 nmol/L), were included, but no data from kidneys given inhibitors were included. Values with a letter in common were not significantly different (P < 0.05).
GFR (glomerular filtration rate) was expressed per gram kidney wet weight. 3 Glucose reabsorption was expressed as percentage of filtered load.
protein. The perfusate supernatant and urine samples were concentrated to dryness (Savant SpeedVac Con centrator, Farmingdale, NY), reconstituted in 2-ME (1.5 mol/L) and stored at -20Â°C for HPLC analysis.
The PAH clearance studies were conducted simi larly except that urine and perfusate aliquots were an alyzed directly by scintillation counting and glucose analysis.
Proper functioning of the IPRK was assessed by monitoring various parameters [urine pH, perfusate pressure and flow, glomerular filtration rate (GFR)] and by determining glucose reabsorption. The amount of glucose in urine and perfusate aliquots was determined enzymatically (Werner et al. 1970) .
Folate clearance determinations. Total radio activity (3H and 14C) in perfusate and urine samples was determined by liquid scintillation analysis using a dual label program. The amount of 5-CH3-H4PteGlu in the samples was determined by HPLC separation of the various folate forms, followed by quantitation by liquid scintillation analysis and by microbiological assay using!, casei (Home and Patterson 1988) . Renal clearance and excretion values for 5-CH3-H4PteGlu, PAH and glucose were calculated as described previ ously (Muldoon et al. 1992) .
HPLC analysis. Folate derivatives were sepa rated as previously described (Eisenga et al. 1989a ) using ion pair HPLC. A gradient elution at a flow rate of 2 mL/min was used, starting with 15% methanol-water containing 5 mmol/L tetrabutylammonium phosphate and increasing in a stepwise fashion to 30% methanol-water over 30 min. The HPLC elution fractions were analyzed for folate derivatives by L. casei microbiological assay and 3H-label by liquid scintillation counting. The per centage of 5-CH3-H4PteGlu in the samples was de termined by calculating becquerels in the 5-CH3-H4PteGlu peak and dividing by the total becquerels eluted from the column. The amount of 5-CH3-H4PteGlu in each sample was calculated from the percentage of 5-CH3-H4PteGlu â€¢ total 3H-label in each sample.
In vitro renal metabolism. Studies were per formed to assess the effect of probenecid on the renal metabolism of 5-CH3-H4PteGlu. The left kidney from male Sprague-Dawley rats (right kidney used in per fusion experiments) was removed, weighed, minced in an equal volume of normal saline, and then ho mogenized for 30 s (Tissumizer, Tek-Mar, Cincinnati, OH). The homogenate was divided into two equal vol umes. Probenecid, to make a concentration of 1 mmol/ L or an equal amount of dilute NaOH, was added to the two portions, which were pre-incubated at 37Â°C for 15 min. Then [3H]-5-CH3-H4PteGlu (111 kBq, 69 pmol) was added to each solution and allowed to in cubate at 37Â°Cfor 60 min. The reaction was stopped by boiling in 2 volumes of 2-ME (1.5 mol/L) for 10 min. The solutions were cooled on ice and centrifuged at 3000 X g (Servali RT6000B, Dupont, Wilmington, DE) for 20 min. The supernatant was filtered (Â¿tStar syringe filters, 0.45 firn, Costar, Cambridge, MA) and stored at 0Â°Cfor HPLC analysis of folates as above. Boiled controls were prepared by heating the homogenates in a boiling water bath for 10 min and cooling at 37Â°Cprior to the addition of 5-CH3-H4PteGlu. Statistical analysis. A computer-generated SAS applications package was used for statistical calcula tions (Statistical Analysis System Version 6.03, SAS Institute Inc., Cary, NC). Group data for multiple comparisons were analyzed by ANOVA using a gen eral linear models procedure followed by Duncan's multiple range test to test for differences among groups. The level of significance used in all studies was P < 0.05. All values represent the mean Â±SEM.
RESULTS
The functional behavior of the IPRK (Table 1) was similar to previous results (Muldoon et al. 1992 ) and within the accepted range for these preparations (Maack 1980) . Functional parameters were generally maintained for at least 2 h (including the 80-min col- lection period). Urine flow increased throughout the perfusion, as noted previously (Muldoon et al. 1992) , probably because the high perfusate flow eventually leads to a disruption of the medullary osmotic gradient (Bowman 1975) . Nevertheless, consistent glucose reabsorption demonstrated the functional stability of the preparation throughout the experimental period. The addition of PteGlu and/or 5-CH3-H4PteGlu (as described below) had no effect on IPRK function.
Because of its higher affinity for the FR, PteGlu was co-administered with 5-CH3-H4PteGlu to assess the contribution of the FR in the tubular reabsorption of 5-CH3-H4PteGlu. The FR binds PteGlu (Kj = 0.4 nmol/ L) with much higher affinity,~six-to sevenfold higher, than 5-CH3-H4PteGlu (Kd= 3 nmol/L) in cul tured monkey kidney cells (Kamen and Capdevilla 1986) and 5.25-fold higher in brush border membranes of rat kidney (Selhub and Rosenberg 1978) . In a first series of studies, PteGlu was added to the perfusate at a concentration one fifth that of 5-CH3-H4PteGlu. Because plasma folate concentrations in male SpragueDawleys rats generally range from 50 to 100 nmol/L (McMartin et al. 1989) , 5-CH3-H4PteGlu was perfused at concentrations well above and below physiologic levels (1, 5, 50, 200, and 2000 nmol/L). Throughout the perfusion period, reabsorption of 5-CH3-H4PteGlu was very consistent, (92.0 Â± 0.6, 92.2 Â± 1.2, 91.7 Â±1.2 and 90.2 Â±1.6% of filtered load at a dose of 50 nmol/ L for collection periods 1-4, respectively).
There was a significant concentration-dependent effect of 5-CH3-H4PteGlu reabsorption observed within the control (5-CH3-H4PteGlu only) experi ments (Fig. 1) . Maximal reabsorption of 91.5% of the filtered load of 5-CH3-H4PteGlu occurred at 50 nmol/L concentration, which was significantly dif ferent than that at the 1200, and 2000 nmol/L con centrations. In these studies, addition of PteGlu had no effect on the percentage of 5-CH3-H4PteGlu reabsorbed in the IPRK (Fig. 1) . Similarly, the amount of 5-CH3-H4PteGlu reabsorbed by the IPRK was not significantly inhibited by PteGlu addition (Fig. 2) . Furthermore, the reabsorptive capacity of the IPRK was not saturated at the levels of 5-CH3-H4PteGlu utilized in the present studies (Fig. 2) .
In a second experiment, the effect of increasing amounts of PteGlu (0, 0.2, 1, 10, 100 nmol/L) on 5-CH3-H4PteGlu reabsorption was examined, when 5-CH3-H4PteGlu was perfused at a concentration of 1 nmol/L (well below the physiologic range). At this low level of 5-CH3-H4PteGlu, FR-dependent transport of MULDOON ET AL. the vitamin would be expected to be the predominant mechanism for tubular reabsorption (Kamen et al. 1991) . However, PteGlu addition did not inhibit the percentage of 5-CH3-H4PteGlu reabsorbed from the filtrate at any concentration used in the present studies (Fig. 3) . There appeared to be a small decrease when the PteGlu concentration was 100 times that of 5-CH3-H4PteGlu, but this effect was not significantly different than the controls (no PteGlu). At these concentrations of PteGlu, there were no differences observed in the functional behavior of the IPRK.
Then 5-CH3-H4PteGlu was perfused at a level above the physiologic range (200 nmol/L), and increasing amounts of PteGlu (0, 40, 200 and 1000 nmol/L) were added. Again, PteGlu had no effect on the percentage of 5-CH3-H4PteGlu reabsorbed from the filtered load (Fig. 4) . Some changes in the functional behavior of the IPRK occurred at the highest dose of PteGlu (1000 nmol/L), including a significant increase in urine flow and a significant decrease in glucose reabsorption. Urine flow increased from 0.28 Â± 0.03 to 0.42 Â± 0.03 mL/min and glucose reabsorption decreased from 97.9 Â± 0.69 to 89.8 Â± 0.88% at 0 and 1000 nmol/L PteGlu, respectively.
The HPLC analysis of urine samples showed a met abolic pattern consisting of three peaks: unchanged 5-CH3-H4PteGlu, a small amount of H4PteGlu and an unidentified, nonfolate product ( Table 2 ). The un identified peak had characteristics similar to one re ported in vivo (Eisenga et al. 1989a ) and was consid ered a nonfolate product, because it did not support the growth of L. casei or elute with any of the folate standards employed in these studies (which included 10-HCO-H4PteGlu, 5-HCO-H4PteGlu, H4PteGlu, 5-CH3-H4PteGlu and PteGlu). The nonfolate peak pos sibly represented one of the folate catabolites identi fied by Murphy et al. (1978) in rat urine. The HPLC analysis showed that 5-CH3-H4PteGlu was the only folate present in the perfusate (except when PteGlu was co-administered). As noted in Table 2 , PteGlu (100 nmol/L) administration did not alter the urinary met abolic pattern of 5-CH3-H4PteGlu (1 nmol/L). These results are consistent with those reported previously (Muldoon et al. 1992 ) and indicate that 5-CH3-H4PteGlu is reabsorbed, metabolized, and possibly catabolized in the IPRK.
Probenecid, an inhibitor of aniÃ³n transport (Pritchard 1988) Bars with the same letter are not different (P > 0.05). controls). However, this treatment markedly altered the urinary metabolic pattern (Table 2) . Normally, 5-CH3-H4PteGlu and a nonfolate accounted for the ma jority of the radiolabeled compounds in urine, along with a small amount of H4PteGlu. The addition of probenecid (1 mmol/L) practically eliminated the presence of H4PteGlu and greatly reduced the non folate compound. To study whether probenecid af fected the metabolism of 5-CH3-H4PteGlu in kidney tissues directly, renal homogenates were prepared. The 5-CH3-H4PteGlu was readily metabolized by renal ho mogenates in vitro (39.6 Â± 4.6% remaining after l h incubation compared with 96.3 Â±0.1%remaining in boiled-homogenate controls, n = 3). Probenecid, at 1 mmol/L, did not alter the metabolism in renal ho mogenates (41.4 Â± 3.1% remaining after 1 h). Studies were also conducted to ensure that the dose of pro benecid was effective at inhibiting aniÃ³nexchange in the IPRK. Probenecid, at 1 mmol/L, significantly in hibited the fractional excretion of the aniÃ³nPAH by the IPRK (Table 3) . At higher concentrations of pro benecid (a;10 mmol/L), functional changes in the IPRK such as significant increases in urine pH and urine vol ume, and a decrease in glucose reabsorption were noted. These results indicated a general alteration of proximal tubular function at higher probenecid doses, hence studies of 5-CH3-H4PteGlu reabsorption were not conducted at these concentrations of probenecid.
DISCUSSION
Current evidence suggests that the kidney plays an important role in maintaining plasma folate homeostasis via proximal tubular reabsorption of the vitamin (Eisenga et al. 1989b , Landon and Hytten 1971 , McMartin et al. 1986 ). However, the mechanism by which this molecule traverses the tubular epithelium remains to be determined. Data from tissue culture studies have suggested a role for the FR in the cellular uptake of folates (Antony et al. 1985; Kamen et al. 1988) . Another pathway involving a probenecid-sensitive aniÃ³ncarrier mechanism has been identified in MA 104 cells and found to be both FR-dependent and FR-independent (Kamen et al. 1991 ). The IPRK model was utilized in the present studies to assess the con tribution of the FR-mediated and aniÃ³ncarrier-me diated pathways in the tubular reabsorption of 5-CH3-H4PteGlu at the whole-organ level.
The present studies suggest that a FR-dependent pathway is not involved in the major portion of the reabsorption of 5-CH3-H4PteGlu that takes place under physiologic conditions in the IPRK. Because the FR has a much higher affinity for PteGlu than for 5-CH3-H4PteGlu (Kamen and Capdevila 1986; Selhub and Rosenburg 1978) , PteGlu administration should decrease the reabsorption of 5-CH3-H4PteGlu. Indeed, PteGlu has been used as an inhibitor of the FR-dependent transport of 5-CH3-H4PteGlu in cultured cells (Kamen et al. 1991) . However, these studies in the IPRK showed that the addition of PteGlu (up to a 100-fold excess)had no effect on the tubular reabsorption of 5-CH3-H4PteGlu whether 5-CH3-H4PteGlu reabsorption was studied above or be low the physiologic range. Only under conditions of low folate concentrations do in vivo renal clearance studies and tissue culture studies provide convincing evidence to suggest FR-mediated transport. At physiologic con centrations (100 nmol/L) in rats, in vivo renal clearance studies could not demonstrate any differences in the clearance of three folate compounds (PteGlu, 5-CH3-H4PteGlu and methotrexate) with marked differences in affinity for the FR (Selhub et al. 1987) . Differences in clearance in relation to FR affinity were observed only at low substrate concentrations, suggesting a transport role for the FR at low concentrations. In MA 104 cells, FR-mediated transport could be identified only when cells were grown in folate-depleted media (Kamen et al. 1991) , due to an increased expression of FR activity. Thus, the FR pathway may not contribute to 5-CH3-H4PteGlu reabsorption under physiologic conditions such as in the IPRK, because there is a diminished expression of the FR at "high" physiologic concentra tions of folate.
Once folate is bound by the FR, subsequent steps in the transmembrane transport process possibly in clude a probenecid-sensitive aniÃ³ncarrier (Kamen et al. 1991) . In the present studies, probenecid was coadministered with 5-CH3-H4PteGlu to determine if an aniÃ³n carrier participated in the reabsorption of this vitamin in the IPRK. The addition of probenecid at concentrations used in these studies, 1 mmol/L, had no effect on the tubular reabsorption of 5-CH3-H4PteGlu. The marked inhibition of PAH excretion in the IPRK demonstrated that this concentration of probenecid was sufficient to block aniÃ³n carrier mechanisms in the perfused kidney. Previous studies performed on cell cultures showed that both FRdependent and FR-independent transport of 5-CH3-H4PteGlu utilized an aniÃ³ncarrier which could be in hibited by probenecid treatment at a concentration of 10 mmol/L (Kamen et al. 1991) . Such concentrations of probenecid altered the functional viability of the IPRK and could not be used in these studies. The marked effects of probenecid on PAH excretion with out any effect on folate reabsorption suggest that this aniÃ³n exchange mechanism does not regulate the reabsorption of 5-CH3-H4PteGlu in the IPRK. Further studies with other aniÃ³nexchange inhibitors will be needed, however, to assess fully the role of an aniÃ³n carrier in the tubular reabsorption of 5-CH3-H4PteGlu.
Although probenecid did not affect the reabsorption of 5-CH3-H4PteGlu, this treatment did alter the pat tern of folate metabolites in the urine. The urinary metabolic pattern in the absence of probenecid indi cated that significant amounts of metabolism and pos sibly catabolism occurred in the IPRK. The urinary metabolic pattern consisted of an unidentified non folate compound, small amounts of H4PteGlu and varying amounts of 5-CH3-H4PteGlu, which depended on the concentration added to the perfusate. This pat tern is similar to that obtained previously (Muldoon et al. 1992) as well as in in vivo clearance studies (Eisenga et al. 1989b ) and provides further evidence that reabsorbed 5-CH3-H4PteGlu can be metabolized in the IPRK to compounds that are subsequently secreted into the urine. However, in the presence of probenecid, 5-CH3-H4PteGlu was practically the only 3H-labeled folate or nonfolate compound present in the urine, suggesting that probenecid inhibited the efflux of the nonfolate product and H4PteGlu from the renal epi thelium into the tubule. A different explanation for the diminished levels of metabolites in the urine could be that probenecid inhibited the enzymatic conversion of 5-CH3-H4PteGlu to these compounds. However, studies of the 5-CH3-H4PteGlu metabolism in renal homogenates demonstrated that probenecid (1 mmol/ L)did not alter the magnitude of conversion of 5-CH3-H4PteGlu. The primary action of probenecid is likely to be inhibition of the transport of organic anions similar to the folates (Weiner et al. 1964) . Apparently, cellular efflux of folate metabolites proceeds via a pro benecid-sensitive aniÃ³ncarrier.
The IPRK model retains function similar to in vivo models in terms of the renal handling of 5-CH3-H4PteGlu. Renal clearance values of 5-CH3-H4PteGlu over a concentration range of 1-2000 nmol/L averaged 0.20 mL/min in comparison with the value (0.37 mL/ min) in vivo (Selhub et al. 1987) , which represents net reabsorption of the vitamin by the IPRK. At physio logic levels in the rat (50 nmol/L), the clearance of 5-CH3-H4PteGlu averaged 0.05 mL (min-g), indicating effective conservation of the vitamin at this level. The GFR, urine flow, pH and perfusion pressure were sim ilar to previous results (Muldoon et al. 1992 ) and within the accepted range for this preparation (Maack 1980) . Consistent glucose reabsorption throughout the experiment was further indication of the stability of proximal tubule function. These data demonstrate that the renal handling of 5-CH3-H4PteGlu remains intact in the IPRK. Furthermore, previous (Muldoon et al. 1992) and present results have shown that the metab olism of 5-CH3-H4PteGlu in the IPRK generates me tabolites (H4PteGlu) and possibly catabolites (nonfol ate compounds) similar to in vivo models (Eisenga et al. 1989b , Selhub et al. 1987 . Although metabolites or catabolites of 5-CH3-H4PteGlu were present in the urine, 5-CH3-H4PteGlu was the only H3-labeled com pound present in the perfusate, indicating that the metabolites were of renal origin. "Perfusion" of [3H]-5-CH3-H4PteGlu and perfusate in the apparatus (with no kidney) for 2 h resulted in no artifactual breakdown of 5-CH3-H4PteGlu.
These results suggest that the majority of tubular reabsorption of 5-CH3-H4PteGlu in the IPRK under physiologic conditions occurs through nonspecific pathways. Similarly, nonspecific pathways have been shown to mediate the uptake of folates in other human cells. In particular, Antony et al. (1989) , have shown that folate transport at physiologic concentrations (10-250 nmol/L) is mediated by a nonspecific, diffusional pathway in mature erythrocytes. During folate defi ciency states, tubular reabsorption of the vitamin may involve an FR-dependent mechanism, because the ac tivity of the FR should be increased at low extracellular folate levels. Kane et al. (1988) and Kamen and Capdevila (1986) have shown that FR activity is markedly increased when cultured cells are depleted of folate by growth in folate-depleted media. The IPRK would be an excellent model for studying potential nutritionally induced changes in renal folate processing.
